<DOC>
	<DOC>NCT01428518</DOC>
	<brief_summary>This post-marketing surveillance study is designed to collect and assess information on safety and effectiveness of lamotrigine tablets in patients with bipolar disorder in routine clinical practice. ("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)</brief_summary>
	<brief_title>Special Drug Use Investigation for LAMICTAL Bipolar</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<criteria>Patients with bipolar disorder Patients treated with lamotrigine tablets for the first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>